
Background Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is a rapidly evolving virus that can severely impact the cardiovascular system. With new variants, it is important to characterize wave-specific (defined by dominant circulating variants) clinical changes. Methods A multi-center retrospective cohort study of patients hospitalized with SARS-CoV-2 community acquired pneumonia at eight adult acute-care hospitals in the city of Louisville, KY was conducted. Patients hospitalized with Coronavirus Disease 2019 (COVID-19) community acquired pneumonia who experienced a cardiovascular event between March 2020 and July 2022 were included in this analysis. Variant assignment was based on temporal prevalence rather than genomic confirmation, and gaps between study periods reflected intervals during which the three variants were not dominant. Results Wave 1 showed significantly higher right bundle branch block (RBBB) (19.4% vs. 6.1%, P = 0.019) and brain natriuretic peptide (BNP) levels (4,598.73±7,764.72 vs. 1,161.33±3,305.48 pmol/L, P = 0.016) in cardiovascular patients on the first electrocardiogram (ECG). On the event triggered ECG, Wave 1 had higher ventricular/pacing rhythm and ST elevation than Wave 2 (8.9% vs. 2.3%, P = 0.033; 6.9% vs. 1.6%, P = 0.039). Wave 2 demonstrated elevated heart rate on the event triggered ECG among non-survivors (115.23±30.7 vs. 99.23±32.2, P = 0.012) and was associated with intensive care unit [1] length of stay (LOS) (ρ = 0.288, P = 0.045). First troponin and BNP levels in sinus rhythm were higher in Wave 3 than Wave 1 (1.7±3.6 vs. 0.2±0.7, P = 0.046). Wave 3 had shorter hospital LOS for survivors at first ECG (median: 8 days), but higher mortality rates for sinus rhythm at event triggered ECG compared to Wave 1 (7.1% vs. 51.6%, P = 0.029). Conclusion Distinct patterns in ECG parameters, cardiac biomarkers, and clinical outcomes in hospitalized COVID-19 patients offer valuable insight into cardiac manifestations of COVID-19, especially as vaccination rates and clinical practices evolve.
A 58-year-old female with a 15-year history of rheumatoid arthritis (RA) and a history of treatment consisting of methotrexate, hydroxychloroquine, leflunomide, and chronic prednisolone therapy, presented with fever, productive cough, dyspnea, and left leg cellulitis. She developed septic shock complicated by tension pneumothorax requiring emergency thoracostomy and non-ST-elevation myocardial infarction (NSTEMI). Pleural fluid culture grew Cupriavidus pauculus, a rare environmental gram-negative bacillus, alongside Burkholderia cepacia and Candida parapsilosis, indicating polymicrobial infection which was most likely predisposed by patient's immunosuppressed state from RA and prolonged steroid use. Treatment consisted of trimethoprim/sulfamethoxazole, meropenem, fluconazole, and cardiopulmonary support, and culminated in recovery after three weeks. This first reported C. pauculus case from Pakistan highlights diagnostic challenges in immunocompromised hosts and underscores the importance of rapid microbiological characterization and multidisciplinary care when managing sepsis caused by rare pathogens amidst complex comorbidities.
Background: Respiratory syncytial virus (RSV) is a negative sense single-stranded RNA virus (ssRNA) that primarily causes respiratory infections in both children and older adults. We examined clinical characteristics and outcomes of hospitalized adult patients who tested positive for RSV. Methods: This was a multicenter, retrospective, descriptive study that examined adult patients admitted with a positive RSV test over two years across eight hospitals in Orlando, Florida. Results: A total of 120 patients were included, of which 88 (73%) were 60 years old and older. Overall, patients with RSV infection were caucasian (62%) with a median age of 70 years and had diabetes mellitus (42%), cardiovascular disease (38%), or chronic respiratory illnesses (36%). Median body mass index (BMI) was 27.8 kg/m2 and median Charlson Comorbidity Index (CCI) was 5. Median hospital and intensive care unit (ICU) length of stay were 4 and 3 days, respectively. Median hospital length of stay for patients under and above 60 years old was 4 days. Median hospital length of stay for those admitted to the ICU was 10 days. Only one patient received ribavirin; the rest received supportive care. Inpatient mortality rate was 4% (5 patients), 67 (57%) were treated with supplemental oxygen, and 7 (6%) were treated with mechanical ventilation. Overall, there was a 30-day readmission rate of 18% (21 patients). Symptomatic RSV infection was present in 102 patients. The clinical characteristics of patients admitted to non-ICU settings and symptomatic patients overall were similar to the total 120 patients. Patients admitted to the ICU were a median age of 77 years of age, females (58%), caucasians (67%), and had a history of chronic kidney disease (CKD) (42%). Conclusions: RSV infection in adult hospitalized patients was predominantly seen among caucasian patients aged 60 years and older. Diabetes mellitus, cardiovascular disease, and chronic respiratory disease were the predominant comorbidities in this cohort. Of the 120 hospitalizations included in our study, 102 were considered to be symptomatic for RSV. Mortality in our population was low; however, RSV alone still accounts for significant morbidity and consumption of healthcare resources.
Introduction: Bronchiectasis, currently being recognized worldwide, is an abnormal dilatation of the bronchi and bronchioles brought on by recurrent cycles of inflammation and airway infection. Impaired pulmonary function has a predictive significance in bronchiectasis. When treating patients with suspected or confirmed respiratory diseases, pulmonary function tests (PFT) are useful examinations. Very few studies have been done on PFTs in bronchiectasis. The main aim of this study is to study PFTs in bronchiectasis. Method: This is a retrospective observational study done on 50 patients over two years at the tertiary care center. The previous records of patients were collected from the Pulmonary Function Lab. The spectrum of lung functions in patients with bronchiectasis was studied with the parameters in pulmonary function tests to see pre- and post-bronchodilator changes in the study population. Results: After post-bronchodilator use, flow volume curve parameters were significantly increased. The mean responses were significant for both FEV1 (increased from 1.29 to 1.53) and FEV1/FVC (increased from 70.9 to 78.4) criteria. However, there was no significant change for the mean MMEF 25/75 (increased from 1.09 to 1.45) criteria after bronchodilator use. The most common pattern was an obstructive defect 24 (48%). Conclusion: When diagnosing and treating bronchiectasis, lung function tests are a crucial evaluation tool. Objective information regarding the kind and severity of respiratory impairment is provided by lung function testing. An airflow obstruction is the most frequent ventilatory pattern associated with bronchiectasis. There is improvement in FEV1 and FVC following bronchodilator use in bronchiectasis.
Background: During 2019, México’s total public spending on health was 5.43% of the national gross domestic product, making it one of the countries of the Organisation for Economic Co-operation and Development that invested the least in developing public health systems. This study analyzes hospital mortality among intubated patients with laboratory-confirmed COVID-19 according to type of institution in San Luis Potosí, México, from March 18, 2020, to April 7, 2022. Methods: This is a secondary data analysis of publicly available information about mortality among intubated patients with a laboratory-confirmed diagnosis of COVID-19 with respect to the type of hospitalization institution. Results: Multivariate logistic regression models showed that patients admitted to public healthcare institutions had 2.4 times the risk of death compared to those admitted to private healthcare institutions. Conclusion: In public sector institutions, COVID-19 mortality among intubated patients was moderately higher. Further studies are needed to clarify whether or not factors such as decreased availability of infrastructure (such as ventilators, intensive care unit beds, and oxygen reserves), decreased human resources, and high demand for public health services might account for the observed mortality differences.